Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.
The catalyst? Macrogenics' shares took flight after the company announced a licensing deal with Incyte Corp. (NASDAQ: INCY) for its programmed cell-death protein 1 (PD-1) inhibitor, MGA012, that's being assessed in four solid tumor types in an early-stage dose-escalation study.
Image source: Getty Images.
Source: Fool.com
Incyte Corp. Stock
€104.20
0.530%
The stock is one of the favorites of our community with 25 Buy predictions and 1 Sell predictions.
With a target price of 114 € there is a slightly positive potential of 9.4% for Incyte Corp. compared to the current price of 104.2 €.
